|
Cornerstone Therapeutics profit falls on expenses
BusinessWeek Sales of the asthma treatment Zyflo CR and Zyflo doubled to $8.8 million. For the full year, the company earned $6.2 million or 24 cents per share, down from $10.2 million, or 54 cents per share, in 2009. Revenue rose to $125.3 million from $109.6 … Critical Therapeutics Inc. Reports Operating Results (10-K) |
View full post on asthma – Google News